⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Safety of Discontinuing Disease-modifying Therapy in Aging MS Patients: A Single-center Study (P4-6.015)

Cori Polonski Ka-Ho Wong Trieste Francis John Rose

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate safety of discontinuing injectable disease-modifying therapies (DMT) in aging patients with relapsing-remitting Multiple Sclerosis (RRMS) with both clinical outcomes and OCT as a measure of neurodegeneration.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Polonski et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677f57 https://doi.org/10.1212/wnl.0000000000205190

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-term follow-up of patients with multiple sclerosis over age 60: Comparing clinical and radiological outcomes in disease-modifying therapy continuers and discontinuersOriginal Research · 2026
2A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis2024 · 2 citations
3Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple SclerosisCohort Study · 2022 · 54 citations
4Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MSCohort Study · 2026
5Real-world effectiveness of disease-modifying therapies in older adults with multiple sclerosis2024 · 4 citations